Zimbabwe has declined a substantial US health deal worth 367 million US dollars (£272m) spanning five years over Washington's demand for confidential biological samples.
This rejection came to light after a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesman later stated that the United States was seeking biological samples for research and commercial gain but refused to guarantee the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for more dialogue to secure a agreement agreeable to both sides so the nation's critical HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a high court halted a similar deal with the US after concerns were filed about the security of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump stated its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to enhance openness and responsibility.
As per reports, Sixteen African countries have to date agreed to similar agreements, constituting over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration would have delivered immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, with no equivalent promise of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," he stated.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the final treatments would be accessible to our people should a new pandemic arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending frameworks previously established through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This framework is intended to ensure that when a country contributes its information, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections regarding the US deal "are not meant as anti-American sentiment," he added.
"We encourage continued discussions with our US partners on how subsequent collaboration might be designed in a manner that respects the sovereignty and dignity of both nations."
Medical Community Response
Medical experts expressed it acknowledged the government's concerns, but recommended that talks need to persist considering much of the nation's Aids initiatives depended on foreign aid.
"If specific concerns arise, such as those relating to information security or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it said.
The situation highlights the complex challenges between receiving vital international aid and protecting national sovereignty in an ever more data-driven world.